Habiba Atta

Patients with myasthenia gravis (MG) lived 15 to 19 years longer than those with multiple sclerosis (MS) across 4 datasets.

Traveling a greater distance for cataract surgery significantly lowered the odds of receiving it, with each 100 miles cutting odds by 14% overall.

The phase 3 MINT trial found inebilizumab significantly reduced exacerbations and rescue therapy use in patients with generalized myasthenia gravis.

In this analysis, all 4 biologic classes showed reduced risk, and the CV benefit remained consistent across White, Black, and Asian patients.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A poll finds awareness of the mifepristone abortion pill is rising, but safety doubts and legal battles persist.

AI-based diabetic retinopathy screening in primary care meaningfully lowers overall health care costs compared with physician-referral screening.

FDA advisers overrode their own scientists to back 6 peptides for compounding, even as safety data remains thin and gray-market risks persist.

A national survey finds retina specialists tolerate higher GA treatment risks in exchange for greater lesion growth rate reduction.

Most eligible people with multiple sclerosis have never used GLP-1 receptor agonists, despite their potential cardiometabolic benefits.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Rising premiums and out-of-pocket costs top Americans' health care concerns across party lines, a Commonwealth Fund survey finds.

A new $20 billion national strategy targets long-standing gaps in women's health research, care, and funding.

The FDA approved Viatris' Gwyn Lo, a once-weekly low-dose estrogen (20 mcg) contraceptive patch, based on phase 3 LUMINOUS data showing a Pearl Index of 4.14 pregnancies per 100 woman-years and strong adhesion (98.7% intact). It's approved for women with BMI under 30; common side effects included application-site irritation and intercycle bleeding. Available later in 2026.

The OVERLORD-MS trial finds rituximab matches ocrelizumab in relapsing multiple sclerosis, with similar MRI control, relapses, and safety.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Chronic skin disorders are psychologically impacting children and adolescents, reinforcing the need for routine mental health screening.

Oral zasocitinib delivered skin clearance once limited to injectable biologics in phase 3 psoriasis trials, including hard-to-treat sites.

Shahzad Mian, MD, explains dry eye disease symptoms, key risk factors, and practical management strategies like drops and warm compresses.

East Asian patients with generalized myasthenia gravis (gMG) saw meaningful nipocalimab benefits in a Vivacity-MG3 subgroup analysis.

Lack of stable reimbursement is negatively impacting clinical dermatological decisions, said Jane M. Grant-Kels, MD, FAAD.

Dry eye symptoms are often mischaracterized or overlooked due to low awareness, delaying diagnosis and treatment and hurting quality of life.

Diagnostic delays and access barriers continue to affect patients with MS, especially in under-resourced areas, World Brain Day highlights.

Reimbursement fixes, policy corrections, and expanded rural training could close dermatology's rural workforce gap, said Jane Grant-Kels, MD.

CMS proposes major Medicare reforms to ACOs, physician pay, and MIPS reporting, aiming to reward outcomes over service volume by 2029.

KFF poll links social media use and not having a trusted doctor to vaccine myth beliefs, fueling COVID-19 and measles risk.

Telehealth care for atopic dermatitis matched in-person outcomes in a study, signaling a scalable option for underserved patients.

Vaccine news shaping the 2026-2027 immunization season includes major acquisitions, a key FDA panel vote, and new data on influenza vaccine effectiveness.